Lifecore Biomedical (LFCR) Common Equity: 2009-2025
Historic Common Equity for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $1.3 million.
- Lifecore Biomedical's Common Equity fell 88.19% to $1.3 million in Q2 2025 from the same period last year, while for May 2025 it was $1.3 million, marking a year-over-year decrease of 88.19%. This contributed to the annual value of $1.3 million for FY2025, which is 88.19% down from last year.
- Lifecore Biomedical's Common Equity amounted to $1.3 million in Q2 2025, which was down 40.06% from $2.2 million recorded in Q1 2025.
- Lifecore Biomedical's 5-year Common Equity high stood at $202.2 million for Q1 2021, and its period low was -$13.6 million during Q3 2023.
- Its 3-year average for Common Equity is $6.3 million, with a median of $1.8 million in 2023.
- Its Common Equity has fluctuated over the past 5 years, first slumped by 117.41% in 2023, then spiked by 987.19% in 2024.
- Over the past 5 years, Lifecore Biomedical's Common Equity (Quarterly) stood at $155.4 million in 2021, then crashed by 54.23% to $71.1 million in 2022, then crashed by 98.00% to $1.4 million in 2023, then soared by 987.19% to $15.4 million in 2024, then tumbled by 88.19% to $1.3 million in 2025.
- Its Common Equity was $1.3 million in Q2 2025, compared to $2.2 million in Q1 2025 and $15.4 million in Q4 2024.